Exceptional Margins, Broken Revenue Guidance—Credibility at Stake

On the headline, Mitsu looks like a star player—net profit up 566%, EBITDA margin jumped over 1,000 basis points. But flip to the guidance and credibility thread snaps. The company guided for a minimum of 30% revenue growth in FY27 at its prior call. This quarter delivered 11.6% YoY. That's not a miss—it's a crater, and management did not re-state or defend the prior target. Instead, the call pivoted to a vaguer aspiration: ₹1,000 Crore revenue by FY28. The profit beat is real. The revenue story is broken.

Q1 FY27 PAT of ₹8.7 Crore is entirely driven by margin expansion, not volume. Revenue grew 11.6% YoY (₹9.9 Cr absolute), but net profit jumped ₹7.4 Crore year-on-year—a margin swing from 1.54% in Q1 FY26 to 9.2% now. EBITDA margin hit 16.3%, up 1,041 bps. Management attributes this to: (1) product mix shift toward healthcare furniture (higher-margin Furnastra brand), (2) operational efficiency, and (3) cost pass-through to customers (raw material pressure absorbed via monthly pricing). The catch: management itself flagged 16.3% as exceptional and guided for a sustainable 10–12% range. This means the reported PAT leans on margin tailwinds the company admits are elevated. If product mix normalizes or cost-pass-through weakens, the margin compresses toward 10–12%, and profit growth evaporates.

Guidance walked. Prior call: minimum 30% FY27 revenue growth. This call: no quantified FY27 target stated, replaced with ₹1,000 Cr FY28 aspiration (unquantified, horizon-agnostic). Management deflected analyst questions on FY27 revenue path by pivoting to 'bottom line focus'—a red flag that topline delivery is not priority. Margin repriced upward, then hedged. Prior guidance: 10–12% EBITDA sustainable. Q1 delivered 16.3%, but management immediately flagged it exceptional, guiding back to 10–12% as 'normal.' This signals management knows the margin beat is temporary or mix-driven, not structural. IBC vertical introduced (new). Intermediate Bulk Container vertical to launch Q3 FY27 with separate machinery and unquantified capex. Management tone: cautious ('test the water'). No revenue ramp or demand validation disclosed. Capacity expansion live. 3,550 MT/annum capacity already operational, capex ₹2 Cr. Existing utilization at 64% in FY26, so expansion adds 11% asset base while utilization is below theoretical max (85% due to seasonality). Analyst questioned the logic; management justified via 6–9 month lead time but sounded defensive.

The post-result price action tells the story. The stock popped +5.75% on day 1 (margin beat confirmed), built to +16.56% by day 3 (peak enthusiasm), then faded to +12.14% by day 5 (profit-taking kicks in). That the pop held—still +12% by day 5—signals investors believe the margin expansion is real. The fade from day 3 to day 5 suggests skepticism about sustainability or whether the margin justifies the ₹1,000 Cr aspiration. Current price ₹187 sits near the all-time high and above all major moving averages (SMA20 ₹163.54, SMA50 ₹153.15, SMA200 ₹121.81). RSI at 78.8 is overbought—little room for multiple expansion without a fresh catalyst. Volume trend is increasing, signaling retail inflow. Ownership is a red flag: FII/DII at 0% means no institutional buying has occurred. The entire rally is domestic-driven (retail, HNI, possibly local funds). Promoters 67.77% locked (good for alignment), but they're not sellers. The absence of FII participation suggests global investors either haven't woken up to the story or are unconvinced by the guidance walkback and revenue deceleration. 52-week range ₹80.3–₹201.05 shows strong recovery from lows (+132%), but current price near ATH leaves little room for error. If execution stumbles (Q2 revenue stays flat, IBC delays), the stock could retrace 15–20% quickly given overbought technicals and institutional vacuum.